S von Harsdorf

Learn More
The novel selective BCR-ABL Breakpoint cluster region--Abelson murine leukemia viral oncogene homolog 1 (BCR-AML) inhibitor nilotinib (AMN107) is a tyrosine kinase inhibitor that is more potent against leukaemia cells in vitro than imatinib. As nilotinib might be used in the context of allogeneic stem cell transplantation where CD8+ T lymphocytes play a(More)
Despite a growing number of new molecular targets, allogeneic hematopoietic cell transplantation remains the most relevant treatment for adverse risk AML. 1 In order to balance a low therapy-related mortality with high anti-leukemic efficacy relying on the GvL effect, Schmid et al. introduced a sequential therapy approach consisting of cytoreductive(More)
  • 1